Rheumatoid Arthritis
Aurelie Najm AurelieRheumo
3 months ago
Microbiome signature for prediction of response to MTX in RA: Yay or Nay?
Microbiome analysis 60pts, 23 MTX NR
BL enrichment in specific species in MTX NR
Looking at the graphs though, seems to be driven by a few pts
Prediction model doesn't seem to perform greatly
Sens 88% https://t.co/1yrSXdE6DG
Antoni Chan MD (Prof) synovialjoints
3 months ago
Regulate-RA study, first-in-human Phase 1 study data show citrullinated protein (CitP)-targeted CAR-Tregs (SBT777101) are safe and show early efficacy in refractory RA. 67% had ≥50% joint count reduction by Week 4. A novel, non-cytotoxic approach to immune modulation for https://t.co/g153w3XVEK
Aurelie Najm AurelieRheumo
3 months ago
Ph2B RCT of Rosnilimab Tcell depleter (PD-1high Tph/Tfh, Teff)
Wk 12 Primary Endpoint met
Mean change DAS28-CRP at Wk 12
SC rosnilimab 100mg Q4W -2.06
400mg Q4W -2.12
600mg Q2W -2.06
PBO -1.69
>90% peripheral and synovial depletion pathogenic T cells 28 Wk
Safety profile: https://t.co/XyVhJamFdp
Jiha Lee JihaRheum
3 months ago
Not all RA meds are equal for the heart.
In >10K older adults w/ RA, advanced therapies lowered MACE risk (HR 0.63) vs csDMARDs, while GCs ↑ risk (HR 1.54) and undertreatment ↑ it 13-fold.
Control inflammation, protect the heart.
@RheumNow #ACR25 Abstract #2642
David Liew drdavidliew
3 months ago
PD-1 agonist as an induction therapy in refractory RA??
Rosnilimab ph2b:
- still responding 3mo after Rx stopped
- no difference between type of prior b/tsDMARD failure
- safety here looks good *so far*
A lot of cautious excitement in the room for this
#ACR25 LB19 @RheumNow https://t.co/CmfPlP4g0N
Jiha Lee JihaRheum
3 months ago
A new approach in RA:
Rosnilimab targets & depletes PD-1–high pathogenic T cells, acting upstream of cytokine pathways. In Ph2b, all doses improved DAS28-CRP & ACR responses vs placebo, with durable efficacy & good safety.
@RheumNow #ACR25 Abstract#LB19 https://t.co/cIxi7NEu6C
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#ACR25 Abstr#LB19 New T-cell therapy on the block! In Phase 2b RCT of #RA (~50% b/tsDMARD-IR), Rosnilimab, PD-1 agonist met its endpoint (DAS28-CRP) at WK12. Effective despite type of previous therapy. No safety concern/malignancy/death. To proceed to Phase 3 @RheumNow #ACRBest https://t.co/MecTYMpH0o
Richard Conway RichardPAConway
3 months ago
Emery et al. Rosnilimab, selective T cell (PD-1high Tph/Tfh, Teff) monoclonal antibody in RA. Phase 2 RCT. 424 patients. 41% prior bDMARD. 69% CDAI LDA week 14. Week 12 ACR20 70%, ACR50 40%, ACR70 21%. @RheumNow #ACR25 Abstr#LB19 https://t.co/479q6COWvk
Jiha Lee JihaRheum
3 months ago
b/tsDMARD in RA + CKD (eGFR <60)
From >12K pts in CorEvitas:
- overall effective but 30% ↓ CDAI-emission (HR 0.71)
- Findings consistent across TNFi, IL-6i, ABA BCDT, JAKi
@RheumNow #ACR25 A#2640 https://t.co/UOP9ejZKoA
For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive. Yet in practice, many of us continue to reach for upadacitinib when we face challenges in treatment, from rheumatoid arthritis to axial spondyloarthritis.
Nouf Al hemmadi NoufAhmedAlham2
3 months ago
Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO
@Janetbirdope pearls in rheumatology.
Sero negative inflammatory arthritis ? Or is it? Look at the toes for early signs of PsA.
In my clinic ITS inflammatory arthritis to determine etiology .
@RheumNow
#ACR25
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#ACR25 Abstr#LB15 Tell #RA patients on methotrexate that eating high fibre diet is good for them! An RCT showed improved EULAR response vs PBO. Likely due to restoration of Th17/Treg balance @RheumNow https://t.co/NbwQFqJNho
Poster Hall